- Home
- CRIS vs LSTA Comparison
CRIS vs LSTA Comparison
Compare CRIS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- LSTA
- Stock Information
- Founded
- CRIS 2000
- LSTA 1980
- Country
- CRIS United States
- LSTA United States
- Employees
- CRIS N/A
- LSTA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- LSTA Misc Health and Biotechnology Services
- Sector
- CRIS Health Care
- LSTA Health Care
- Exchange
- CRIS Nasdaq
- LSTA Nasdaq
- Market Cap
- CRIS 22.9M
- LSTA 22.3M
- IPO Year
- CRIS 2000
- LSTA N/A
- Fundamental
- Price
- CRIS $1.70
- LSTA $2.15
- Analyst Decision
- CRIS Strong Buy
- LSTA Strong Buy
- Analyst Count
- CRIS 2
- LSTA 2
- Target Price
- CRIS $16.50
- LSTA $23.50
- AVG Volume (30 Days)
- CRIS 75.9K
- LSTA 21.9K
- Earning Date
- CRIS 11-13-2025
- LSTA 11-11-2025
- Dividend Yield
- CRIS N/A
- LSTA N/A
- EPS Growth
- CRIS N/A
- LSTA N/A
- EPS
- CRIS N/A
- LSTA N/A
- Revenue
- CRIS $11,405,000.00
- LSTA $1,070,000.00
- Revenue This Year
- CRIS $1.41
- LSTA N/A
- Revenue Next Year
- CRIS $7.46
- LSTA N/A
- P/E Ratio
- CRIS N/A
- LSTA N/A
- Revenue Growth
- CRIS 12.24
- LSTA N/A
- 52 Week Low
- CRIS $1.02
- LSTA $1.87
- 52 Week High
- CRIS $6.44
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CRIS 47.75
- LSTA 38.47
- Support Level
- CRIS $1.63
- LSTA $2.11
- Resistance Level
- CRIS $1.95
- LSTA $2.33
- Average True Range (ATR)
- CRIS 0.14
- LSTA 0.16
- MACD
- CRIS 0.02
- LSTA -0.01
- Stochastic Oscillator
- CRIS 26.47
- LSTA 14.81
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.